Prognostic utility of apoptosis index, Ki-67 and survivin expression in dogs with nasal carcinoma treated with orthovoltage radiation therapy

Journal of Veterinary Medical Science

Volumn 76, Issue 11, 2014, Pages 1505-1512

  Fu, Dah Renn ^a   Kato, Daiki ^a   Watabe, Ai ^a   Endo, Yoshifumi ^a   Kadosawa, Tsuyoshi ^a  

^a RAKUNO GAKUEN UNIVERSITY   (Japan)

Author keywords

Apoptosis; Canine nasal carcinoma; Ki 67; Prognosis; Survivin

Indexed keywords

CANIS FAMILIARIS;

INHIBITOR OF APOPTOSIS PROTEIN; KI 67 ANTIGEN; TUMOR MARKER;

ANIMAL; APOPTOSIS; CARCINOMA; DOG; DOG DISEASES; KAPLAN MEIER METHOD; METABOLISM; NOSE NEOPLASMS; PHYSIOLOGY; PROGNOSIS; TUNEL ASSAY; VETERINARY;

ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA; DOG DISEASES; DOGS; IN SITU NICK-END LABELING; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; NOSE NEOPLASMS; PROGNOSIS;

EID: 84913573405     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.14-0245     Document Type: Article

References (36)

1. Adams, W. M., Kleiter, M. M., Thrall, D. E., Klauer, J. M., Forrest, L. J., La Due T. A. and Havighurst, T. C. 2009. Prognostic significance of tumor histology and computed tomographic staging for radiation treatment response of canine nasal tumors. Vet. Radiol. Ultrasound50: 330–335.
2. Adell, G. C., Zhang, H., Evertsson, S., Sun, X. F., StÅl, O. H. and Nordenskjöld, B. A. 2001. Apoptosis in rectal carcinoma: prognosis and recurrence after preoperative radiotherapy. Cancer91: 1870–1875.
3. Belshaw, Z., Constantio-Casas, F., Brearley, M. J., Dunning, M. D., Holmes, M. A. and Dobson, J. M. 2011. COX-2 expression and outcome in canine nasal carcinomas treated with hypofrac-tionated radiotherapy. Vet. Comp. Oncol.9: 141–148.
4. Bergkvist, G. T., Argyle, D. J., Morrison, L., MacIntyre, N., Hayes, A. and Yool, D. A. 2011. Expression of epidermal growth factor receptor (EGFR) and Ki67 in feline oral squamous cell carcinomas (FOSCC). Vet. Comp. Oncol.9: 106–117.
5. Bongiovanni, L., Colombi, I., Fortunato, C. and Della Salda, L. 2009. Survivin expression in canine epidermis and in canine and human cutaneous squamous cell carcinomas. Vet. Dermatol.20: 369–376.
6. Freudlsperger, C., Freier, K., Hoffmann, J. and Engel, M. 2012. Ki-67 expression predicts radiosensitivity in oral squamous cell carcinoma. Int. J. Oral Maxillofac. Surg.41: 965–969.
7. Henry, C. J., Brewer, W. G. Jr., Tyler, J. W., Brawner, W. R., Henderson, R. A., Hankes, G. H. and Royer, N. 1998. Survival in dogs with nasal adenocarcinoma: 64 cases (1981–1995). J. Vet. Intern. Med.12: 436–439.
8. Iwasa, T., Okamoto, I., Suzuki, M., Nakahara, T., Yamanaka, K., Hatashita, E., Yamada, Y., Fukuoka, M., Ono, K. and Nakagawa, K. 2008. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin. Cancer Res.14: 6496–6504.
9. Johnson, M. E. and Howerth, E. W. 2004. Survivin: a bifunc-tional inhibitor of apoptosis protein. Vet. Pathol.41: 599–607.
10. Kennedy, A. S., Raleigh, J. A., Perez, G. M., Calkins, D. P., Thrall, D. E., Novotny, D. B. and Varia, M. A. 1997. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int. J. Radiat. Oncol. Biol. Phys.37: 897–905.
11. Knutsen, A., Adell, G. and Sun, X. F. 2004. Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.60: 149–155.
12. Kropveld, A., Slootweg, P. J., Blankenstein, M. A., Terhaard, C. H. and Hordijk, G. J. 1998. Ki-67 and p53 in T2 laryngeal cancer. Laryngoscope108: 1548–1552.
13. LaDue, T. A., Dodge, R., Page, R. L., Price, G. S., Hauck, M. L. and Thrall, D. E. 1999. Factors influencing survival after radiotherapy of nasal tumors in 130 dogs. Vet. Radiol. Ultrasound40: 312–317.
14. Lewis, K. D., Samlowski, W., Ward, J., Catlett, J., Cranmer, L., Kirkwood, J., Lawson, D., Whitman, E. and Gonzalez, R. 2011. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest. New Drugs29: 161–166.
15. Li, Y. H., Hu, C. F., Shao, Q., Huang, M. Y., Hou, J. H., Xie, D., Zeng, Y. X. and Shao, J. Y. 2008. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J. Transl. Med.6: 1.
16. Melzer, K., Guscetti, F., Rohrer Bley, C., Sumova, A., Roos, M. and Kaser-Hotz, B. 2006. Ki67 reactivity in nasal and periocular squamous cell carcinomas in cats treated with electron beam radiation therapy. J. Vet. Intern. Med.20: 676–681.
17. Nakahara, T., Kita, A., Yamanaka, K., Mori, M., Amino, N., Takeuchi, M., Tominaga, F., Kinoyama, I., Matsuhisa, A., Kudou, M. and Sasamata, M. 2011. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci. 102: 614–621.
18. Nichols, A. C., Whelan, F., Basmaji, J., Dhaliwal, S., Dowth-waite, S., Chapeskie, C., Read, N., Palma, D. A., Fung, K., Venkatesan, V., Hammond, J. A., Franklin, J. H., Siddiqui, I., Wehrli, B., Kwan, K., Koropatnick, J., Mymryk, J. S., Barrett, J. W. and Yoo, J. 2012. Ki-67 expression predicts radiotherapy failure in early glottic cancer. J. Otolaryngol. Head Neck Surg.41: 124–130.
19. Northrup, N. C., Etue, S. M., Ruslander, D. M., Rassnick, K. M., Hutto, D. L., Bengtson, A., Rand, W. and Moore, A. S. 2001. Retrospective study of orthovoltage radiation therapy for nasal tumors in 42 dogs. J. Vet. Intern. Med.15: 183–189.
20. Rankin, W. V., Henry, C. J., Turnquist, S. E., Turk, J. R., Beis-senherz, M. E., Tyler, J. W., Rucker, E. B., Knapp, D. W., Rodriguez, C. O. and Green, J. A. 2008. Identification of survivin, an inhibitor of apoptosis, in canine urinary bladder transitional cell carcinoma. Vet. Comp. Oncol.6: 141–150.
21. Rassnick, K. M., Goldkamp, C. E., Erb, H. N., Scrivani, P. V., Njaa, B. L., Gieger, T. L., Turek, M. M., McNiel, E. A., Proulx, D. R., Chun, R., Mauldin, G. E., Phillips, B. S. and Kristal, O. 2006. Evaluation of factors associated with survival in dogs with untreated nasal carcinomas: 139 cases (1993–2003). J. Am. Vet. Med. Assoc.229: 401–406.
22. Rebhun, R. B., Lana, S. E., Ehrhart, E. J., Charles, J. B. and Thamm, D. H. 2008. Comparative analysis of survivin expression in untreated and relapsed canine lymphoma. J. Vet. Intern. Med.22: 989–995.
23. Rödel, C., Haas, J., Groth, A., Grabenbauer, G. G., Sauer, R. and Rödel, F. 2003. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivi-ties: survivin as a radioresistance factor. Int. J. Radiat. Oncol. Biol. Phys.55: 1341–1347.
24. Rödel, C., Grabenbauer, G. G., Papadopoulos, T., Bigalke, M., Günther, K., Schick, C., Peters, A., Sauer, R. and Rödel, F. 2002. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.52: 294–303.
25. Rödel, C., Grabenbauer, G. G., Rödel, F., Birkenhake, S., Kühn, R., Martus, P., Zörcher, T., Fürsich, D., Papadopoulos, T., Dunst, J., Schrott, K. M. and Sauer, R. 2000. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int. J. Radiat. Oncol. Biol. Phys.46: 1213–1221.
26. Scase, T. J., Edwards, D., Miller, J., Henley, W., Smith, K., Blunden, A. and Murphy, S. 2006. Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. J. Vet. Intern. Med.20: 151–158.
27. Sheridan, M. T., Cooper, R. A. and West, C. M. 1999. A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys.44: 507–512.
28. Shoeneman, J. K., Ehrhart, E. J. 3rd., Eickhoff, J. C., Charles, J. B., Powers, B. E. and Thamm, D. H. 2012. Expression and function of survivin in canine osteosarcoma. Cancer Res.72: 249–259.
29. Sittel, C., Ruiz, S., Volling, P., Kvasnicka, H. M., Jungehüls-ing, M. and Eckel, H. E. 1999. Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. Oral Oncol. 35: 583–589.
30. Tannapfel, A., Nüsslein, S., Fietkau, R., Katalinic, A., Köcker-ling, F. and Wittekind, C. 1998. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemo-therapy for locally advanced rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.41: 585–591.
31. Théon, A. P., Madewell, B. R., Harb, M. F. and Dungworth, D. L. 1993. Megavoltage irradiation of neoplasms of the nasal and paranasal cavities in 77 dogs. J. Am. Vet. Med. Assoc.202: 1469–1475.
32. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., Van Oosterom, A. T., Christian, M. C. and Gwyther, S. G. 2000. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst.92: 205–216.
33. Wheeler, J. A., Stephens, L. C., Tornos, C., Eifel, P. J., Ang, K. K., Milas, L., Allen, P. K. and Meyn, R. E. Jr. 1995. ASTRO Research Fellowship: apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys.32: 1487–1493.
34. Yamanaka, K., Nakahara, T., Yamauchi, T., Kita, A., Takeuchi, M., Kiyonaga, F., Kaneko, N. and Sasamata, M. 2011. Antitu-mor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin. Cancer Res.17: 5423–5431.
35. Yip, K. W., Shi, W., Pintilie, M., Martin, J. D., Mocanu, J. D., Wong, D., MacMillan, C., Gullane, P., O’Sullivan, B., Bas-tianutto, C. and Liu, F. F. 2006. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin. Cancer Res.12: 5726–5732.
36. Zhang, Y., Huang, D. and Yu, G. 2005. Survivin expression and its relationship with apoptosis and prognosis in nasal and paranasal sinus carcinomas. Acta Otolaryngol. 125: 1345–1350.